Although targeting USP8 has the potential to synergize with cancer immunotherapy despite the completely different results obtained for PD-L1 expression, the treatment window for combination therapy should be carefully evaluated because the half-life of DUB-targeted substrates might significantly determine the efficacy of ICB. The gene discussed is USP8; the disease is cancer.